Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

Summary

This is a randomized, single-center phase 3 clinical trial without blinding. Iguratimod, as a rheumatoid arthritis medication, is used to treat autoimmune diseases such as Sjögren's syndrome. It has acceptable side effects, good clinical availability, and is cost-effective. The investigators plan to recruit participants for a clinical trial to evaluate the efficacy and safety of Iguratimod in the treatment of chronic GVHD.

Timeline

Start

2024-01-10

Primary completion

2027-06-01

Completion

2028-12-31

Drugs

Indications